Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3; Protocol No. P04938)

Next Previous
X
Search
Trial Profile

A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3; Protocol No. P04938)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Preladenant (Primary) ; Rasagiline
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Fulford; Merck & Co; Merck Sharp & Dohme; Schering-Plough; Schering-Plough Research Institute

    • Most Recent Events

    • 02 Nov 2015 Results of pooled analysis of two phase 3 trials (NCT01155466 and NCT01227265) published in the JAMA Neurology
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 01 May 2014 Primary endpoint 'Off-time' has not been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top